General
Preferred name
bucillamine
Synonyms
DE-019 ()
Thiobutarit ()
Tiobutarit ()
SA96 ()
DE 019 ()
DE019 ()
Rimatil ()
Bucilamina ()
Bucilant ()
P&D ID
PD013922
CAS
65002-17-7
Tags
drug
available
Drug Status
approved
investigational
Max Phase
3.0
Drug indication
Rheumatoid arthritis
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis. (TargetMol Bioactive Compound Library)
Compound Sets
10
ChEMBL Drugs
CHEMBL80830
Drug Repurposing Hub
DrugBank
DB12160
DrugCentral
414
DrugCentral Approved Drugs
414
MedChem Express Bioactive Compound Library
HY-118530
Natural product-based probes and drugs
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
T21334
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
223.03
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
4
Ring Count
0
Aromatic Ring Count
0
cLogP
0.19
TPSA
66.4
Fraction CSP3
0.71
Chiral centers
1.0
Largest ring
0.0
QED
0.51
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
VEGFR
antioxidant
Indication
rheumatoid arthritis
MOA
Immunosuppressant
Biosynthetic Origin
Other (Amino Acid)
Therapeutic Indication
Immunomodulator
Therapeutic Class
Immunomodulatory
Pathway
Protein Tyrosine Kinase/RTK
Angiogenesis
oxidation-reduction
Tyrosine Kinase/Adaptors
Source data